GlassScriptPhysician profile
James Mark Dorn
NPI 1578532347
$5,329.87
in general payments reported to CMS, 2019-2025
34 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $514 · 2022: $849 · 2023: $1,268 · 2024: $1,556 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,966.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $897.39 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $652.73 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $460.31 | 2022-2025 | |
| Pfizer INC. | $445.63 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $417.22 | 2022-2025 | |
| Amgen INC. | $274.35 | 2021-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $265.44 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Teva Pharmaceuticals USA, INC. | $219.13 | 2022-2024 | Ajovy |
| Novartis Pharmaceuticals Corporation | $209.37 | 2021-2025 | |
| Dexcom, INC. | $170.74 | 2021-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $143.75 | 2022-2024 | Quviviq |
| Glaxosmithkline, LLC. | $125.01 | 2021-2025 | Shingrix, Trelegy Ellipta, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.77 | 2021-2025 | Tradjenta, Synjardy, Jardiance |
| Janssen Pharmaceuticals, INC | $108.87 | 2022-2024 | Spravato, Xarelto |
| Merck Sharp & Dohme LLC | $108.25 | 2021-2025 | Gardasil 9, Vaxelis, Capvaxive |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $75.40 | 2023-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Esperion Therapeutics, INC. | $70.47 | 2021-2024 | Nexletol |
| Exact Sciences Corporation | $63.17 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $54.14 | 2022 | |
| Antares Pharma, INC. | $48.97 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Lundbeck LLC | $46.29 | 2023-2024 | Vyepti |
| Abbott Laboratories | $46.05 | 2024-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $42.46 | 2024-2025 | Voquezna |
| Dynavax Technologies Corporation | $34.98 | 2023-2024 | Heplisav-B |
| Sanofi-Aventis U.S. LLC | $34.63 | 2021-2023 | |
| Halozyme INC | $33.39 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.31 | 2021 | |
| Clarus Therapeutics INC. | $25.27 | 2021 | |
| Daiichi Sankyo INC. | $23.05 | 2024 | Injectafer |
| Cranial Technologies, INC | $20.69 | 2025 | Doc Band |
| Amneal Pharmaceuticals LLC | $18.32 | 2023 | Lyvispah |
| Astellas Pharma US INC | $17.51 | 2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $15.97 | 2025 | Gvoke Hypopen |
| Corcept Therapeutics | $14.84 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Dorn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.